So for ER+ cancers, cells can become dormant and evade treatment. This targeted treatment might be able to avoid that problem and even prevent us from having to do up to 10 years of anti-hormone treatment. Interesting.

I asked my oncologist about Signatera but they don't use it for detecting recurrence, only to monitor treatment of reoccurrence.